Investment Proposals
“Aigul” Virtual Assistant – AI & VR Platform for Training and Personnel Assessment
Key Indicators/Results:
- Investment amount: USD 650,000
- Project NPV, thousand USD –
- IRR, % –
- EBITDA margin, % –
- Payback period, years –
- Discounted payback period, years –
Location:
Republic of Kazakhstan
Project Objective:
To accelerate the development of an ecosystem of adaptive AI-powered digital assistants with LVA analytics, customized for HR, training, and customer service in the B2B segment, with expansion into international markets.
Project Description:
“Aigul” is a digital employee developed using generative AI, virtual reality (VR), and voice analytics (LVA) technologies. The project addresses corporate training, recruitment, and personnel assessment tasks. The product is actively used in retail, industry, banking, and the public sector.
Key Features:
- Interactive employee training through VR simulations;
- Emotional and cognitive analysis using LVA technology;
- Staff adaptation and onboarding in a dialogue format;
- Assessment of stress resilience, engagement, and loyalty.
Implemented and pilot projects include major banks, retailers, manufacturing enterprises, as well as the Ministry of Internal Affairs and the Ministry of Emergency Situations of Kazakhstan.
Investment Highlights:
- Required investment: from USD 650,000
- Investor participation format: SAFE agreement / equity participation / strategic partnership
- Project stage: scaling; working product available; pilots and LOIs signed
- Plan: ARR of USD 10–15M achievable within 2 years (1% of CIS market share)
Advantages:
- AI-based personalized training
- Unique emotion and cognitive state analysis technology
- Strong B2B interest (50+ active leads)
- Graduated from MOST IT HUB and Industrial AI Accelerator
- Supported by Astana Hub, MES, and Akimat of Almaty
Market & Potential:
Target audience: large companies in Kazakhstan and the CIS seeking HR digitalization and sustainable development.
Expansion potential to Central Asia and the Middle East.
TAM: USD 15B – global market for digital avatars, online learning, and HR-Tech
SAM: USD 1.2B – CIS B2B segment (VR training, chatbots, AI assistants)
DENTAL IMPLANTS AND PROSTHETICS MANUFACTURING
Key Indicators:
- Investment: USD 2.2M
- NPV: USD 1.4M
- IRR: 22.4%
- Payback period: 5.1 years
- Discounted payback period: 7.6 years
Project:
Construction of a dental implant and prosthetics manufacturing plant in the Special Economic Zone “Park of Innovative Technologies” in Almaty.
Production capacity: up to 120,000 units per year.
Product Range (at full capacity by 2031):
- Implants – 30,000 units
- Healing abutments – 21,000 units
- Abutments – 21,000 units
- Fixation screws – 21,000 units
- Transfers and analogs – 21,000 units
44% of output will be sold domestically, with the remainder exported to Central Asian countries.
Project Attractiveness:
- Favorable SEZ location and logistics
- Import substitution potential
- Equipment and materials from Japan (TSUGAMI), Germany (Zapp Precision Metals GmbH), and the USA (Himed)
Required financing: USD 2.2M (70% debt, 30% investor participation).
CONSTRUCTION OF A CHEESE AND HORECA FOOD PRODUCTION PLANT
Key Indicators:
- Investment: USD 8.63M
- NPV: USD 8.322M
- IRR: 21.3%
- Payback period: 4.45 years
- Discounted payback period: 5.99 years
Project:
Construction of a plant in the Industrial Zone of Almaty for the production of cheese and other food products for the HoReCa sector.
Planned Production Volumes (by 2027):
- Butter – 432 tons
- Cheese – 648 tons
- Ricotta – 78 tons
- Albumin cottage cheese – 104 tons
- Nut assortments – 27,000 tons
- Tomato sauces – 68 tons
- Dried apples and pears – 34 tons each
80% for the domestic market; 20% for export (Russia, South Korea, UAE).
Project Attractiveness:
- Access to strong raw material base
- Environmentally friendly production
- Import substitution opportunity
Required investment: USD 8.63M (70% debt, 30% investor participation).
PHARMACEUTICAL PRODUCTION
Key Indicators:
- Investment: USD 95M
- NPV: USD 26.5M
- IRR: 25.6%
- EBITDA margin: 53%
- Payback period: 7.68 years
- Discounted payback period: 12.96 years
Project:
Construction of a full-cycle pharmaceutical manufacturing plant in the Special Economic Zone “Park of Innovative Technologies” in Almaty.
The plant (28,500 sq. m.) will operate in compliance with GMP, GLP, and GDP standards under the European MHRA framework.
Production Capacity:
- Solid dosage forms – 8.199 million packs
- Liquid dosage forms – 2.985 million packs
- 87 branded generics covering antibiotics, analgesics, hormonal, cardiovascular, anti-anemia, vitamin, antidiabetic, neurological, psychiatric, gastrointestinal, and oncology medicines.
Project Attractiveness:
- Strong government support and guaranteed procurement priority for domestic producers
- SEZ tax and customs exemptions
- Founders with over 10 years of pharmaceutical manufacturing management experience
Required financing: USD 95M (80% debt financing, 20% investor participation).